City Thera targets $175 million IPO to advance RNA drugs

12 October 2026

US biotech City Therapeutics is seeking about $175 million in an initial public offering (IPO) to support three experimental RNA medicines, with clinical milestones approaching across programs targeting blood clots, eye disease and anemia.

The Cambridge, Massachusetts-based company set proposed terms on October 9, offering approximately 9.7 million shares at $17 to $19 each. The $175 million target reflects gross proceeds at the $18 midpoint, before underwriting discounts and offering expenses. City has applied to list on Nasdaq under the symbol CTY.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Biotechnology